Onconova Therapeutics(ONTX)2024-11-14 21:40Financial Performance - As of September 30, 2024, Traws Pharma had cash, cash equivalents, and short-term investments of approximately 20.8 million at December 31, 2023[6] - The net loss for Q3 2024 was 8.81 per share, compared to a net loss of 5.64 per share, for the same period in 2023[9] - Traws Pharma's total operating expenses for Q3 2024 were 5.1 million in Q3 2023, reflecting a significant increase in R&D and G&A costs[15] - The company reported total liabilities of approximately 12.01 million at the end of 2023[14] - Traws Pharma's accumulated deficit increased to approximately 482.6 million at the end of 2023[14] Research and Development - Research and development (R&D) expenses for Q3 2024 totaled 2.5 million for the same period in 2023[7] - Phase 1 data for ratutrelvir indicates potential for once-a-day dosing without ritonavir, showing no treatment-related adverse events and consistent plasma drug levels[3] - Tivoxavir marboxil demonstrated good tolerability in Phase 1 studies, maintaining plasma drug levels above the EC90 for over five days, supporting its potential as a single-dose treatment for influenza[4] - Traws Pharma plans to initiate Phase 2 clinical proof of concept studies for both tivoxavir marboxil and ratutrelvir in community-acquired settings in 2025[3] General and Administrative Expenses - General and administrative (G&A) expenses for Q3 2024 were 2.7 million in Q3 2023, primarily due to a $1.2 million increase in professional and consulting fees[8]